Current Trials in Florida

1		Recruiting		Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-Remitting Multiple Sclerosis
				Condition:		Multiple Sclerosis
				Interventions:		Drug: Fingolimod;   Drug: Fingolimod;   Drug: Fingolimod matching placebo
2		Recruiting		Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
				Condition:		Relapsing-Remitting Multiple Sclerosis
				Intervention:		Drug: BG00012
3		Recruiting		Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
				Condition:		Relapsing Remitting Multiple Sclerosis
				Interventions:		Drug: Interferon beta 1-a;   Drug: glatiramer acetate;   Other: placebo
4		Recruiting		Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
				Condition:		Multiple Sclerosis, Relapsing-Remitting
				Interventions:		Biological: alemtuzumab;   Biological: alemtuzumab;   Biological: interferon beta-1a (Rebif®)
5		Recruiting		Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
				Condition:		Multiple Sclerosis, Relapsing-Remitting
				Interventions:		Biological: alemtuzumab;   Biological: interferon beta-1a (Rebif®)
6		Recruiting		Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
				Condition:		Relapsing-Remitting Multiple Sclerosis
				Intervention:		Drug: BG00012
7		Recruiting		Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
				Condition:		Secondary Progressive Multiple Sclerosis
				Interventions:		Drug: natalizumab;   Other: standard of care
8		Recruiting		12-Week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
				Condition:		Multiple Sclerosis
				Interventions:		Drug: CS-0777 tablets;   Drug: CS-0777 tablets;   Drug: CS-0777 tablets;   Drug: CS-0777 matching placebo tablets
9		Recruiting		Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
				Condition:		Multiple Sclerosis
				Interventions:		Drug: CDP323;   Drug: placebo;   Drug: CDP323
10		Recruiting		A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
				Condition:		Multiple Sclerosis
				Interventions:		Drug: interferon beta-1a;   Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: placebo
11		Recruiting		Observational Study to Determine Impact of Multiple NAb Tests on Treatment Patterns Compared to the Usual Care of MS Patients Receiving High-Dose IFN Therapy.
				Condition:		Multiple Sclerosis
				Intervention:		Procedure: NAbs testing
12		Recruiting		Evaluation of Natalizumab for thE Relief of MS Associated FatiGue
				Condition:		Multiple Sclerosis
				Intervention:
13		Recruiting		BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon â-1a (Avonex®)
				Condition:		Multiple Sclerosis
				Interventions:		Drug: laquinimod;   Drug: placebo;   Drug: Interferon â-1a (Avonex®)
14		Recruiting		Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
				Condition:		Pseudobulbar Affect (PBA)
				Intervention:		Drug: AVP-923